{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:54:29Z","timestamp":1791323669406,"version":"4.3.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,6]],"date-time":"2027-08-06T00:00:00Z","timestamp":1817510400000},"content-version":"am","delay-in-days":309,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM008620"],"award-info":[{"award-number":["T32GM008620"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jvir.2026.108954","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:19:55Z","timestamp":1783628395000},"page":"108954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2060-8964","authenticated-orcid":false,"given":"Ricardo","family":"Azevedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5947-5313","authenticated-orcid":false,"given":"David","family":"Imagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3634-9039","authenticated-orcid":false,"given":"Marianne","family":"Rara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9891-2653","authenticated-orcid":false,"given":"Hannah","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6513-6618","authenticated-orcid":false,"given":"Kellie","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-7746","authenticated-orcid":false,"given":"Jennifer","family":"Valerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1912-3441","authenticated-orcid":false,"given":"Fa-Chyi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4970-5189","authenticated-orcid":false,"given":"Farshid","family":"Dayyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5649-1433","authenticated-orcid":false,"given":"Dayantha","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6163-8524","authenticated-orcid":false,"given":"Nadine","family":"Abi-Jaoudeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2026.108954_bib1","series-title":"Cancer facts & figures 2025","year":"2025"},{"key":"10.1016\/j.jvir.2026.108954_bib2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jvir.2026.108954_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jvir.2026.108954_bib4","unstructured":"National Comprehensive Cancer Network. Pancreatic adenocarcinoma version 2.2025. NCCN clinical practice guidelines in oncology. Pennsylvania: NCCN."},{"key":"10.1016\/j.jvir.2026.108954_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/cancers10010016","article-title":"Locally advanced pancreatic cancer: a review of local ablative therapies","volume":"10","author":"Ruarus","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jvir.2026.108954_bib6","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2026.108954_bib7","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2026.108954_bib8","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1245\/s10434-021-10991-2","article-title":"Neoadjuvant chemotherapy switch in borderline resectable\/locally advanced pancreatic cancer","volume":"29","author":"Alva-Ruiz","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jvir.2026.108954_bib9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/MPA.0000000000001345","article-title":"Benefit of gemcitabine\/nab-paclitaxel rescue of patients with borderline resectable or locally advanced pancreatic adenocarcinoma after early failure of FOLFIRINOX","volume":"48","author":"Vreeland","year":"2019","journal-title":"Pancreas"},{"key":"10.1016\/j.jvir.2026.108954_bib10","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1245\/s10434-016-5373-2","article-title":"Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer","volume":"23","author":"Rombouts","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jvir.2026.108954_bib11","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jvir.2026.108954_bib12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S2468-1253(24)00017-7","article-title":"MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial","volume":"9","author":"Timmer","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jvir.2026.108954_bib13","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1007\/s00330-024-10613-x","article-title":"Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study","volume":"34","author":"Tasu","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jvir.2026.108954_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1193040","article-title":"Irreversible electroporation combined with chemotherapy and PD-1\/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jvir.2026.108954_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.622318","article-title":"Survival comparison of neoadjuvant chemotherapy followed by irreversible electroporation versus conversional resection for locally advanced pancreatic cancer","volume":"10","author":"He","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jvir.2026.108954_bib16","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.jvir.2020.02.024","article-title":"Value of CT-guided percutaneous irreversible electroporation added to FOLFIRINOX chemotherapy in locally advanced pancreatic cancer: a post hoc comparison","volume":"31","author":"van Veldhuisen","year":"2020","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2026.108954_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1148\/radiol.2019191109","article-title":"Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): a multicenter, prospective, single-arm, phase II study","volume":"294","author":"Ruarus","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2026.108954_bib18","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.12998\/wjcc.v8.i22.5564","article-title":"Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer","volume":"8","author":"Ma","year":"2020","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jvir.2026.108954_bib19","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2147\/OTT.S186721","article-title":"Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study","volume":"12","author":"Liu","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jvir.2026.108954_bib20","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.hpb.2018.12.004","article-title":"A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry","volume":"21","author":"Holland","year":"2019","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jvir.2026.108954_bib21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12885-019-5607-3","article-title":"Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis","volume":"19","author":"He","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jvir.2026.108954_bib22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jvir.2016.10.023","article-title":"Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma","volume":"28","author":"Narayanan","year":"2017","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2026.108954_bib23","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jvir.2012.09.012","article-title":"Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma","volume":"23","author":"Narayanan","year":"2012","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2026.108954_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10439-005-8981-8","article-title":"Tissue ablation with irreversible electroporation","volume":"33","author":"Davalos","year":"2005","journal-title":"Ann Biomed Eng"},{"key":"10.1016\/j.jvir.2026.108954_bib25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/153303460700600407","article-title":"The effect of irreversible electroporation on blood vessels","volume":"6","author":"Maor","year":"2007","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.jvir.2026.108954_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvir.2020.100675","article-title":"Irreversible electroporation for locally advanced pancreatic cancer","volume":"23","author":"Timmer","year":"2020","journal-title":"Tech Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2026.108954_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.radonc.2014.10.015","article-title":"SBRT in pancreatic cancer: what is the therapeutic window?","volume":"114","author":"Brunner","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jvir.2026.108954_bib28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-0045-1801889","article-title":"Complications of percutaneous irreversible electroporation for pancreatic cancer: a systematic review","volume":"9","author":"Bhatia","year":"2025","journal-title":"J Clin Interv Radiol"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044326009656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044326009656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:47:53Z","timestamp":1791323273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044326009656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1051044326009656"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2026.108954","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2026.108954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 SIR, 2026","name":"copyright","label":"Copyright"}],"article-number":"108954"}}